Phase 3 Results With Dual Therapy Cabotegravir/Rilpivirine Long-Acting Injections: ATLAS and FLAIR Studies
Two oral presentations at CROI 2019 showed that dual therapy with long-acting monthly injections resulted in very low levels of virological failure with high participant preference for injections compared to oral combinations.
In clinical trials called Sword 1 and Sword 2, researchers testing a combination of dolutegravir/rilpivirine (Juluca) found it to be effective and tolerable.
Once viable long-acting HIV prevention and treatment options have reached the market, what will be their true impact? Leading HIV clinician-researcher Anton Pozniak, M.D., shares his expertise.
Long-acting antiretrovirals: Are they the future of HIV treatment or will the future pass them by? Researcher Charles W. Flexner recently addressed several common myths.
"This is really the first step in demonstrating that two-drug regimens can be as effective as three-drug regimens," says Kimberly Smith, M.D., M.P.H.
A single intramuscular dose of long-acting rilpivirine (Edurant) significantly lowered HIV in rectal tissue but not in vaginal or cervical tissue, according to a recent study.
Rilpivirine (Edurant) remained detectable in plasma and female genital tract fluids for 18 months or more after a single injection of a long-acting non-nucleoside for HIV pre-exposure prophylaxis (PrEP).
Maintenance HIV Regimen of Rilpivirine and Boosted Darunavir as Effective as Three-Drug Treatment in Early Results
Rilpivirine (Edurant) plus ritonavir-boosted darunavir (Prezista) as HIV maintenance therapy compared similarly to a three-drug regimen of a boosted protease inhibitor and two nucleoside reverse transcriptase inhibitors, according to a study presente...
Three posters at CROI 2015 described pharmacokinetics of antiretrovirals in pregnancy for rilpivirine, etravirine and raltegravir. None of the studies suggested that dose adjustment is required.
HIV treatment remains far from perfect, and there are still seats at the table available for improved antiretrovirals. Paul Sax, M.D., provides an update on several of the most noteworthy candidates currently in development.